South Korea · Delayed Price · Currency is KRW NGeneBio Statistics
Total Valuation
NGeneBio has a market cap or net worth of KRW 16.31 billion. The enterprise value is 42.13 billion.
| Market Cap | 16.31B |
| Enterprise Value | 42.13B |
Important Dates
The next estimated earnings date is Friday, August 14, 2026.
| Earnings Date | Aug 14, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
NGeneBio has 8.94 million shares outstanding. The number of shares has increased by 51.09% in one year.
| Current Share Class | 8.94M |
| Shares Outstanding | 8.94M |
| Shares Change (YoY) | +51.09% |
| Shares Change (QoQ) | +3.82% |
| Owned by Insiders (%) | 7.02% |
| Owned by Institutions (%) | 0.51% |
| Float | 7.65M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 0.52 |
| PB Ratio | 0.74 |
| P/TBV Ratio | 0.94 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 1.35 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 0.48, with a Debt / Equity ratio of 1.48.
| Current Ratio | 0.48 |
| Quick Ratio | 0.39 |
| Debt / Equity | 1.48 |
| Debt / EBITDA | n/a |
| Debt / FCF | -1.03 |
| Interest Coverage | -2.98 |
Financial Efficiency
Return on equity (ROE) is -29.04% and return on invested capital (ROIC) is -12.45%.
| Return on Equity (ROE) | -29.04% |
| Return on Assets (ROA) | -9.66% |
| Return on Invested Capital (ROIC) | -12.45% |
| Return on Capital Employed (ROCE) | -33.23% |
| Weighted Average Cost of Capital (WACC) | 7.08% |
| Revenue Per Employee | n/a |
| Profits Per Employee | n/a |
| Employee Count | n/a |
| Asset Turnover | 0.62 |
| Inventory Turnover | 15.54 |
Taxes
| Income Tax | -965.45M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -72.46% in the last 52 weeks. The beta is 0.78, so NGeneBio's price volatility has been lower than the market average.
| Beta (5Y) | 0.78 |
| 52-Week Price Change | -72.46% |
| 50-Day Moving Average | 3,418.12 |
| 200-Day Moving Average | 4,806.01 |
| Relative Strength Index (RSI) | 22.81 |
| Average Volume (20 Days) | 60,430 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, NGeneBio had revenue of KRW 31.20 billion and -7.00 billion in losses. Loss per share was -873.48.
| Revenue | 31.20B |
| Gross Profit | 4.24B |
| Operating Income | -7.80B |
| Pretax Income | -6.31B |
| Net Income | -7.00B |
| EBITDA | -6.05B |
| EBIT | -7.80B |
| Loss Per Share | -873.48 |
Balance Sheet
The company has 6.41 billion in cash and 32.68 billion in debt, with a net cash position of -26.27 billion or -2,939.30 per share.
| Cash & Cash Equivalents | 6.41B |
| Total Debt | 32.68B |
| Net Cash | -26.27B |
| Net Cash Per Share | -2,939.30 |
| Equity (Book Value) | 22.12B |
| Book Value Per Share | 2,525.41 |
| Working Capital | -24.95B |
Cash Flow
In the last 12 months, operating cash flow was -5.19 billion and capital expenditures -26.63 billion, giving a free cash flow of -31.82 billion.
| Operating Cash Flow | -5.19B |
| Capital Expenditures | -26.63B |
| Depreciation & Amortization | 1.75B |
| Net Borrowing | 22.66B |
| Free Cash Flow | -31.82B |
| FCF Per Share | -3,560.73 |
Margins
Gross margin is 13.60%, with operating and profit margins of -25.00% and -22.43%.
| Gross Margin | 13.60% |
| Operating Margin | -25.00% |
| Pretax Margin | -20.24% |
| Profit Margin | -22.43% |
| EBITDA Margin | -19.39% |
| EBIT Margin | -25.00% |
| FCF Margin | n/a |
Dividends & Yields
NGeneBio does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -51.09% |
| Shareholder Yield | -51.09% |
| Earnings Yield | -42.92% |
| FCF Yield | -195.11% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on July 13, 2026. It was a reverse split with a ratio of 0.3333333333.
| Last Split Date | Jul 13, 2026 |
| Split Type | Reverse |
| Split Ratio | 0.3333333333 |
Scores
NGeneBio has an Altman Z-Score of -1.3 and a Piotroski F-Score of 2. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -1.3 |
| Piotroski F-Score | 2 |